Mawer Investment Management Ltd. purchased a new stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,725 shares of the company’s stock, valued at approximately $525,000.
Other institutional investors and hedge funds have also modified their holdings of the company. Diversified Trust Co acquired a new position in Moderna during the third quarter worth $810,000. Aberdeen Group plc lifted its position in shares of Moderna by 6,931.1% in the third quarter. Aberdeen Group plc now owns 1,054,306 shares of the company’s stock worth $203,028,000 after buying an additional 1,039,311 shares during the last quarter. Allworth Financial LP lifted its position in shares of Moderna by 9.7% in the third quarter. Allworth Financial LP now owns 4,523 shares of the company’s stock worth $871,000 after buying an additional 400 shares during the last quarter. SVB Wealth LLC acquired a new stake in shares of Moderna in the third quarter worth about $266,000. Finally, Russell Investments Group Ltd. lifted its position in shares of Moderna by 18.9% in the third quarter. Russell Investments Group Ltd. now owns 531,893 shares of the company’s stock worth $102,551,000 after buying an additional 84,445 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.
Insider Activity
In other news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the transaction, the insider directly owned 74,129 shares in the company, valued at approximately $10,374,353.55. The trade was a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 39,145 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $220.72, for a total value of $8,640,084.40. Following the transaction, the president directly owned 1,636,565 shares of the company’s stock, valued at $361,222,626.80. This represents a 2.34% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 197,251 shares of company stock valued at $33,875,904. 10.80% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
MRNA has been the topic of a number of analyst reports. The Goldman Sachs Group increased their price objective on Moderna from $137.00 to $195.00 and gave the company a “neutral” rating in a report on Monday, November 9th. Berenberg Bank raised their price objective on Moderna from $45.00 to $100.00 and gave the company a “hold” rating in a research note on Friday, September 11th. JPMorgan Chase & Co. boosted their target price on Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a report on Friday, August 21st. CLSA raised Moderna to an “outperform” rating in a research report on Friday, August 28th. Finally, Piper Sandler reiterated an “overweight” rating and set a $305.00 price target (up from $230.00) on shares of Moderna in a report on Monday, November 9th. Six investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $113.75.
Get Our Latest Stock Report on Moderna
Trending Headlines about Moderna
Investors following MRNA have been watching these headlines:
- Positive Sentiment: Moderna lifted its 2026 revenue-growth forecast to 15%–25%, from a previous outlook of up to 10%, citing commercial progress including stronger overseas COVID-19 sales. Article
- Positive Sentiment: The company highlighted progress in its oncology pipeline, including its personalized cancer vaccine, positioning cancer treatments as a potential longer-term growth driver. Article
- Neutral Sentiment: Moderna is scheduled to join the MSCI World Index in November, which could broaden its investor reach. It also reported peer-reviewed real-world data on its mNEXSPIKE COVID-19 vaccine in older adults; the reports provided limited detail on the potential commercial impact. Article
Moderna Stock Performance
Shares of MRNA opened at $223.37 on Monday. The company has a market capitalization of $90.38 billion, a PE ratio of -31.46 and a beta of 1.16. Moderna, Inc. has a one year low of $22.28 and a one year high of $280.80. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47. The company’s fifty day moving average price is $201.67 and its 200 day moving average price is $96.41.
Moderna (NASDAQ:MRNA – Get Free Report) last released its earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. During the same quarter in the previous year, the business earned ($0.51) EPS. The business’s revenue was up 29.2% on a year-over-year basis. As a group, analysts expect that Moderna, Inc. will post -5.14 earnings per share for the current year.
Moderna Company Profile
Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.
Featured Stories
- Five stocks we like better than Moderna
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
